Trial Finds Bimagrumab Aids Weight Loss in Patients With T2D, Obesity
January 18th 2021, 7:21pm
ArticleResults of a phase 2 trial showed that an activin type II receptor blockade, achieved via bimagrumab, led to significant loss of fat mass, gain in lean mass, and metabolic improvements among patients with type 2 diabetes (T2D) and overweight or obesity.